BackBayer CropScience Limited Overview

Bayer CropScience Limited EBIT

Bayer CropScience Limited's EBIT is $9.4B, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$2.03B
↓ 0.98% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$9.39B
↑ 40.12% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Bayer CropScience Limited (BAYERCROP.NS) FAQ

The latest EBIT for BAYERCROP.NS is $9.4B as of September 2026. That compares with $6.7B in the prior-year period — up 40.1% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Bayer CropScience Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, BAYERCROP.NS's EBIT moved from $6.7B to $9.4B — a 40.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bayer CropScience Limited's operating scale or balance-sheet position.

Against its sector companies, BAYERCROP.NS currently prints $9.4B for EBIT, while the sector average sits near $2.4T. That is roughly 99.6% below the sector mean. Large gaps often invite a closer look at Bayer CropScience Limited's growth, margins, and balance sheet.

A EBIT figure of $9.4B for BAYERCROP.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting BAYERCROP.NS's EBIT ($9.4B), review year-over-year change from $6.7B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers